A Phase II Clinical Study of Fruquintinib Combined With Sintilimab and SOX as Conversion Therapy of Potentially Resectable Stage IV Gastric Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Fruquintinib (Primary) ; Oxaliplatin (Primary) ; Sintilimab (Primary)
Indications Adenocarcinoma; Colon cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer
Focus Therapeutic Use

04 Jun 2024 Results(From May 2022 to December 2023, n=34 pts) focusing on efficacy and safety of fruquintinib combined with sintilimab and SOX as a conversion therapy in patients, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
23 May 2024 According to a HUTCHMED media release, data from this study will be presented at the upcoming American Society of Clinical Oncology Annual Meeting, taking place May 31 - June 4, 2024 in Chicago, IL and online.
17 Aug 2022 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com